Literature DB >> 18344868

Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei.

Jesse K McKenney1, Robert A Soslow, Teri A Longacre.   

Abstract

Mucinous epithelial neoplasms arising in association with mature teratomas are a heterogeneous group of tumors, but with the exception of a single recent study, their full histologic spectrum, detailed immunophenotype, and association with classic pseudomyxoma peritonei (PMP) have not been fully studied. The morphologic, immunohistochemical, and clinical features of 42 patients with mucinous epithelial tumors arising in association with mature ovarian teratomas were evaluated. The patients' ages ranged from 17 to 66 years (mean, 39 y). Tumor size ranged from 5.5 to greater than 200 cm. Most teratoma-associated mucinous tumors were unilateral, although 1 patient harbored bilateral mucinous tumors in association with bilateral teratomas. In all cases, the teratomatous component consisted of mature elements. Using the 2003 World Health Organization criteria for ovarian intestinal type mucinous neoplasms, 17 (40%) were classified as mucinous cystadenoma, 16 (38%) as intestinal-type mucinous epithelial neoplasm of low malignant potential (IM-LMP), 4 (10%) as intraepithelial carcinoma (IEC), and 5 (12%) as invasive mucinous carcinoma. Mucinous cystadenomas had a varied epithelial lining consisting of lower gastroenteric, gastric foveolar, or müllerian appearance. In contrast, the IM-LMP, IEC, and invasive carcinoma cases had a more uniform lower gastroenteric histology. For mucinous cystadenomas, a cytokeratin (CK) 7+/CK20- phenotype (5/13; 38%) was equally as common as a CK7-/CK20+ phenotype (5/13; 38%), with the remaining cases coexpressing both keratins (CK7+/CK20+: 3/13; 23%). In contrast, IM-LMP, IEC, and invasive adenocarcinomas more frequently had a CK7-/CK20+ phenotype (56%, 50%, and 100%, respectively). A CK7+/CK20-phenotype was rare in these later 3 morphologic groups (6%). Of the 42 total cases, 55% had pseudomyxoma ovarii and 24% had classic PMP (1 cystadenoma, 6 IM-LMP, and 3 invasive carcinomas), whereas 5% had more localized accumulations of peritoneal mucin (both IM-LMP). Pathologic evaluation of the peritoneum in these 12 cases revealed 6 with acellular mucin alone, 3 with low-grade mucinous epithelium (all 3 with ovarian IM-LMP), and 3 with high-grade mucinous carcinomatosis (all 3 with ovarian mucinous adenocarcinoma). No appendiceal lesions were identified. Follow-up was available in 48% of patients (mean, 61 mo). The only adverse outcomes occurred in the 3 patients with ovarian carcinoma and associated peritoneal carcinomatosis. We report that a significant proportion of mucinous tumors associated with mature ovarian teratomas present with clinical PMP, which in most cases is associated with IM-LMP. PMP in this setting may harbor microscopic intra-abdominal low-grade mucinous epithelium that is histologically and immunophenotypically similar to that typically seen in appendiceal-related PMP. Pseudomyxoma ovarii is common in this setting, particularly in tumors with IM-LMP histology, but pseudomyxoma ovarii is not predictive of PMP. Ovarian teratoma-associated benign and IM-LMP mucinous neoplasms with microscopic peritoneal low-grade mucinous epithelium do not seem to be at significant risk for intra-abdominal recurrence, but numbers are few and follow-up is limited. In contrast, teratomas with an invasive carcinomatous component and microscopic peritoneal carcinomatosis follow an aggressive clinical course.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18344868     DOI: 10.1097/PAS.0b013e31815b486d

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  27 in total

1.  Collision tumours of ovary: a very rare case series.

Authors:  Ajay Kr Singh; Monika Singh
Journal:  J Clin Diagn Res       Date:  2014-11-20

2.  Two types of primary mucinous ovarian tumors can be distinguished based on their origin.

Authors:  Michiel Simons; Femke Simmer; Johan Bulten; Marjolijn J Ligtenberg; Harry Hollema; Shannon van Vliet; Richarda M de Voer; Eveline J Kamping; Dirk F van Essen; Bauke Ylstra; Lauren E Schwartz; Yihong Wang; Leon F Massuger; Iris D Nagtegaal; Robert J Kurman
Journal:  Mod Pathol       Date:  2019-11-06       Impact factor: 7.842

3.  Mucinous Cystadenocarcinoma Co-Existing with Mature Cystic Teratoma : A Rare Case Report.

Authors:  Prachi Kukreja; Sunil Kumar Yeshvanth; Teerthanath Shrinivas; Tanu Agrawal; Jayaprakash K Shetty
Journal:  J Clin Diagn Res       Date:  2015-07-01

Review 4.  Diagnosis, treatment, and follow-up of borderline ovarian tumors.

Authors:  Daniela Fischerova; Michal Zikan; Pavel Dundr; David Cibula
Journal:  Oncologist       Date:  2012-09-28

Review 5.  A guided tour of selected issues pertaining to metastatic carcinomas involving or originating from the gynecologic tract.

Authors:  Robert A Soslow; Rajmohan Murali
Journal:  Semin Diagn Pathol       Date:  2017-11-20       Impact factor: 3.464

6.  Clinicopathologic and immunohistochemical profile of ovarian metastases from colorectal carcinoma.

Authors:  Gozde Kir; Ayse Gurbuz; Ates Karateke; Mustafa Kir
Journal:  World J Gastrointest Surg       Date:  2010-04-27

7.  Mature embryoid teratoma in the wall of a mucinous cyst adenoma of ovary in multiparous female.

Authors:  Mohammed Naim; Nazima Haider; Vanesa T John; Seema Hakim
Journal:  BMJ Case Rep       Date:  2011-02-02

Review 8.  [Mucinous ovarian neoplasms. Prognostically mostly excellent, infrequently a wolf in sheep's clothing].

Authors:  S Lax; A Staebler
Journal:  Pathologe       Date:  2014-07       Impact factor: 1.011

Review 9.  Pathology of Mucinous Appendiceal Tumors and Pseudomyxoma Peritonei.

Authors:  Veena Ramaswamy
Journal:  Indian J Surg Oncol       Date:  2016-03-19

Review 10.  Ovarian and non-ovarian teratomas: a wide spectrum of features.

Authors:  Tsukasa Saida; Kensaku Mori; Tomohiko Masumoto; Sodai Hoshiai; Toshitaka Ishiguro; Masafumi Sakai; Tadashi Hara; Hiroyuki Ochi; Toyomi Satoh; Manabu Minami
Journal:  Jpn J Radiol       Date:  2020-09-01       Impact factor: 2.374

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.